2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6300 Patient-reported distress and symptom burden trajectories during chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) patients

Irin Hoque Bhuiya, N/A, Noel Estrada-Merly, MS2, Aniko Szabo, PhD3, Ravi Kishore Narra, MD.,MS4, Sabarinath Venniyil Radhakrishnan, MD5, Othman Salim Akhtar, MD6, Binod Dhakal, MD, MS7, Anita D'Souza, MD8
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, University of Wisconsin- Milwaukee, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is a high-intensity treatment currently approved in relapsed/refractory multiple myeloma (MM) with high response rates and durable remissions. Patients receiving CAR-T therapy often experience significant early treatment-associated toxicities which may place them at risk for psychological distress and symptom burden. However, the prevalence, severity, and trajectory of patient-reported distress during CAR-T therapy remain understudied. To understand these patterns, we evaluated patient-reported distress and symptom burden over time and identified factors associated with increased distress before and after CAR-T.

Methods: We included patients with MM who received CAR-T therapy between 11/1/2021-05/31/2026 and had pre/post-CAR-T distress surveys. Sociodemographic characteristics [age, sex, race/ethnicity, marital and employment status (full-time or part-time employed, retired, disabled)], clinical characteristics [MM subtype, ISS stage, cytogenetic risk, Karnofsky Performance Status (KPS), pulmonary, cardiac and renal comorbidities, prior lines of therapy (LOT) and CAR-T product], and post-treatment outcomes (CRS, infection, and relapse after CAR-T) were collected. Distress was obtained from completed National Comprehensive Cancer Network Distress Thermometer/Problem List surveys recorded in the electronic health record from 120 days before to 420 days after CAR-T infusion. Associations between distress scores (0, no distress to 10, worst distress) and baseline characteristics were evaluated using linear mixed-effects models with restricted maximum likelihood estimation, including patient-specific random intercepts and slopes to account for repeated assessments. Time was modeled continuously as months from infusion date assessment. Post-treatment outcomes were analyzed as time-dependent covariates. A second model incorporated between-patient and within-patient components of physical, emotional, practical, and social concerns.

Results: Of 114 MM patients who received CAR-T therapy (median age at infusion: 67 years, range: 25-85.0; 63% male; 84% non-Hispanic White and 4% non-Hispanic Black; 68% married; 55% retired; 55% high-risk disease; 44% had KPS 90%-100%; 28% had cardiac comorbidity and 6% had renal comorbidity; 89% received ciltacabtagene autoleucel and 11% received idecabtagene vicleucel; 13% had <=2 LOT; 48% had 3-4 LOT and 38% had >= 5 LOT).  The mean interval between the first two surveys was 203 days (Q1-Q3: 181-247 days) and the mean distress score change was -0.27 (SD 2.63). In the mixed-effects model evaluating factors associated with distress over time, distress scores decreased over time (β=-0.08 per month, p=0.02). Female sex was associated with higher distress compared with males (β=1.37, p=0.008), as were renal comorbidity (β=1.98, p=0.034) and post-CAR-T relapse (β=2.23, p=0.008). Adjusting for physical, emotional, practical, and social domains, the association between time and distress was attenuated and no longer statistically significant (β=-0.04 per month, p=0.203). Older patients reported higher distress [patients aged 60-69 years (β=1.42, p=0.012) and ≥70 years (β=1.55, p=0.017)]. Disability was associated with higher distress (β=1.58, p=0.014) and full-time employment status showed a trend toward higher distress (β=1.21, p=0.073). Female sex (β=0.91, p=0.027), renal comorbidity (β=-1.86, p=0.013), and relapse status (β=1.76, p=0.012) remained significant. Higher average physical concerns (β=0.37, p<0.001) and within-person increases in physical burden (β=0.34, p<0.001) were associated with higher distress. Higher average emotional concerns (β=0.35, p<0.001), and within-person increases of emotional concerns (β=0.80, p<0.001) over time were strongly related to increased distress. Higher pre-CAR-T practical concerns were also associated with greater post-CAR-T distress (β=1.16, p=0.018).

Conclusion: Patient-reported distress decreased over time following CAR-T therapy, presumably with better MM control. However, this decline became statistically nonsignificant after adjusting for patient-reported concerns. Physical, emotional, and practical concerns correlated with higher distress. Female sex, renal comorbidity, relapse status, age, and disability also correlated with distress. Routine distress screening with early intervention and distress management may help improve supportive care and survivorship with MM CAR-T therapy.
Irin Hoque Bhuiya, N/A: No relevant conflicts of interest to declare.